Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: JEB who wrote (30)	10/31/2000 7:30:44 PM
From: BulbaMan	Read Replies (1) \| Respond to of 1784

Posted 10/31/00 on SI Trickle My pick for the "Trickle" portfolio is SMDX (SpectruMedix). As a micro-micro-cap (under $10 million market-cap), the upside is enormous. They've recently made sales to Vogelstein's oncology lab at John Hopkins and a major European seed company. Also, PE Biosystems' investment in SMDX helps their credibility. Here's a blurb on SMDX from their latest press release: "SpectruMedix develops and manufactures high-speed and high throughput DNA sequencing and genetic analysis instrumentation for the acquisition, analysis and management of complex genetic information and high-throughput screening, massive parallel capillary electrophoresis systems for drug discovery. The DNA sequencing and high-throughput screening instrumentation were developed in part from research efforts conducted at the U.S. Department of Energy's Ames Laboratory, which is operated by Iowa State University's Institute for Physical Research and Technology. SpectruMedix is also involved in the development of instrumentation and methodology to rapidly assess lung function in all pulmonary diseases, in order to improve evaluation, diagnosis and treatment in such patients."